A drug of Jiangsu Hengrui Medicine's (SHA:600276) unit, Suzhou Shengdia Biopharmaceutical, was included in the proposed breakthrough therapy products list of China's National Medical Products Administration.
The drug is trastuzumab for injection, a drug used to treat patients with ovarian cancer and primary peritoneal cancer, according to a Shanghai Stock Exchange disclosure on Monday.
The drug will be included in the regulator's breakthrough therapy program, the pharmaceutical company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments